Abstract Details
|
Steven Edland
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| Guerry M. Peavy, PhD (University of California, San Diego) | Dr. Peavy has stock in MRK. Dr. Peavy has stock in ABT. Dr. Peavy has stock in JNJ. Dr. Peavy has stock in ABBV. The institution of an immediate family member of Dr. Peavy has received research support from NIH. The institution of Dr. Peavy has received research support from NIH. |
| David P. Salmon, PhD (Univ of Calif-San Diego) | Dr. Salmon has nothing to disclose. |
| Douglas Galasko, MD (Dept. of Neurosciences, UCSD) | Dr. Galasko has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Galasko has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for vTv Therapeutics. Dr. Galasko has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fujirebio. Dr. Galasko has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Esai. Dr. Galasko has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics. Dr. Galasko has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for BioMed Central. |